🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Laurus Labs Limited LAURUSLABS NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.lauruslabs.com
Company Profile ↓
₹1,840.00
+121.84% 1Y
Mkt Cap₹99,333.61 Cr
P/E111.85
P/B18.79
Div. Yield0.13%
52W High₹1,938.50
52W Low₹829.44
Book Value₹98.18
EPS (TTM)₹16.45

Company Overview

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.5%.

Healthy Margins

Operating margin of 19.4% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,721.23 Cr (+22.0% YoY); net profit ₹888.79 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.0%, earnings +148.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.8%, profit CAGR 4.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.77%
1 Year:22.03%

Compounded Profit Growth

5 Years:4.00%
1 Year:148.04%

Stock Price Performance

1 Year:+121.84%
6 Months:+79.48%
3 Months:+29.18%
1 Month:+0.55%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 91% of range
₹829.44 ₹1,938.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)54.19 · Neutral
Price Performance
1M+0.55%
3M+29.18%
6M+79.48%
1Y+121.84%
Valuation vs Sector

P/E of 111.85 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 111.8.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
111.85
Industry PE
41.64
Forward P/E
64.17
PEG Ratio
-
Book Value
₹98.18
Price to Book
18.79
P/S
13.71
EV/EBITDA
50.02
Dividend Yield
0.13%

Growth (CAGR)

Revenue 5Y
3.77%
Profit 5Y
4.00%
Revenue (YoY)
22.03%
Earnings (YoY)
148.04%

Profitability & Returns

ROCE
19.53%
ROE
16.77%
ROA
8.46%
Profit Margin
13.22%
Op Margin
19.44%
Gross Margin
58.88%
EPS (Latest Qtr)
₹6.80
EPS (TTM)
₹16.45

Balance Sheet & Liquidity

Debt/Equity
0.48
Quick Ratio
0.68
Current Ratio
1.33
Debt
₹2,518.48 Cr
Total Assets
₹10,511.19 Cr
Current Assets
₹4,829.21 Cr
Working Capital
₹1,193.78 Cr

Ownership

Promoter Holding
32.03%
Chg in Prom Hold
-
FII / Inst Holding
32.59%
Chg in FII Hold
2.97%

Financial Snapshot

Enterprise Value
₹99,333.61 Cr
Total Revenue (TTM)
₹6,721.23 Cr
EBITDA
₹1,822.98 Cr
Free Cash Flow
₹553.55 Cr
Operating Cash Flow
₹1,623.50 Cr
Shares Outstanding
₹53.99 Cr
Gross Margin
58.88%
Payout Ratio
9.89%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,110.00 18.12 ₹96,464.79 Cr 0.75% 28.33% 23.76% 19.10% 131.46%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 1,381.00 Cr1,182.00 Cr1,224.00 Cr1,195.00 Cr1,440.00 Cr1,195.00 Cr-1,415.05 Cr1,720.30 Cr1,569.57 Cr1,653.00 Cr1,778.29 Cr1,811.57 Cr2,026.31 Cr
Cost of Revenue -------610.15 Cr782.68 Cr637.35 Cr-694.57 Cr700.10 Cr756.01 Cr
Gross Profit -------804.90 Cr937.62 Cr932.22 Cr-1,083.72 Cr1,111.47 Cr1,270.30 Cr
Operating Expenses 1,095.00 Cr1,015.00 Cr1,037.00 Cr1,014.00 Cr1,198.00 Cr1,024.00 Cr-625.84 Cr627.45 Cr666.93 Cr1,250.00 Cr724.13 Cr721.46 Cr755.90 Cr
Operating Income 199.00 Cr76.00 Cr95.00 Cr83.00 Cr139.00 Cr65.00 Cr-179.06 Cr310.17 Cr265.29 Cr283.00 Cr359.59 Cr390.01 Cr514.40 Cr
EBITDA 286.00 Cr167.00 Cr188.00 Cr181.00 Cr241.00 Cr171.00 Cr-294.57 Cr479.17 Cr392.56 Cr403.00 Cr485.97 Cr523.91 Cr647.45 Cr
Interest Expense 53.00 Cr39.00 Cr42.00 Cr51.00 Cr50.00 Cr49.00 Cr-57.80 Cr56.40 Cr51.50 Cr40.00 Cr38.79 Cr40.44 Cr42.22 Cr
Pretax Income 147.00 Cr41.00 Cr54.00 Cr35.00 Cr107.00 Cr18.00 Cr-130.68 Cr312.34 Cr224.22 Cr270.00 Cr326.56 Cr361.37 Cr481.36 Cr
Tax Provision 39.69 Cr12.30 Cr14.58 Cr9.45 Cr32.10 Cr6.12 Cr-40.07 Cr78.47 Cr63.14 Cr75.60 Cr73.45 Cr79.46 Cr119.37 Cr
Net Income 105.00 Cr27.00 Cr37.00 Cr23.00 Cr75.00 Cr13.00 Cr-92.30 Cr233.67 Cr163.02 Cr194.00 Cr251.66 Cr279.14 Cr367.60 Cr
Diluted EPS 1.910.460.690.431.400.230.371.714.333.023.614.655.176.80

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,327.00 Cr1,778.00 Cr1,905.00 Cr2,056.00 Cr2,292.00 Cr2,832.00 Cr4,814.00 Cr-6,014.22 Cr5,001.80 Cr5,507.86 Cr6,721.23 Cr
Cost of Revenue --------2,840.71 Cr2,499.09 Cr2,539.41 Cr2,763.59 Cr
Gross Profit --------3,173.51 Cr2,502.71 Cr2,968.45 Cr3,957.64 Cr
Operating Expenses 1,126.00 Cr1,415.00 Cr1,497.00 Cr1,642.00 Cr1,935.00 Cr2,266.00 Cr3,262.00 Cr-1,879.24 Cr2,107.84 Cr2,343.27 Cr2,651.27 Cr
Operating Income 138.00 Cr276.00 Cr302.00 Cr289.00 Cr193.00 Cr378.00 Cr1,347.00 Cr-1,294.27 Cr394.87 Cr625.18 Cr1,306.37 Cr
EBITDA 200.00 Cr362.00 Cr408.00 Cr414.00 Cr357.00 Cr565.00 Cr1,552.00 Cr-1,555.91 Cr792.70 Cr1,120.98 Cr1,822.98 Cr
Interest Expense 106.00 Cr111.00 Cr100.00 Cr80.00 Cr88.00 Cr90.00 Cr68.00 Cr-122.89 Cr171.76 Cr206.59 Cr161.05 Cr
Pretax Income 67.00 Cr169.00 Cr234.00 Cr237.00 Cr120.00 Cr294.00 Cr1,301.00 Cr-1,108.94 Cr236.36 Cr484.29 Cr1,181.88 Cr
Tax Provision -1.34 Cr35.49 Cr44.46 Cr68.73 Cr26.40 Cr38.22 Cr312.24 Cr-312.30 Cr68.15 Cr129.88 Cr292.03 Cr
Net Income 68.00 Cr134.00 Cr190.00 Cr168.00 Cr94.00 Cr255.00 Cr984.00 Cr-790.11 Cr160.55 Cr358.32 Cr888.79 Cr
Diluted EPS 8.8116.973.603.161.764.7718.33-14.642.976.6416.45

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,888.00 Cr2,224.00 Cr2,653.00 Cr3,017.00 Cr3,331.00 Cr3,750.00 Cr5,751.00 Cr-7,660.40 Cr8,387.03 Cr9,335.57 Cr10,511.19 Cr
Current Assets --------3,461.68 Cr3,834.97 Cr4,332.32 Cr4,829.21 Cr
Cash & Equivalents --------45.67 Cr138.94 Cr99.54 Cr112.65 Cr
Inventory --------1,684.81 Cr1,845.41 Cr1,936.54 Cr2,342.16 Cr
Receivables --------1,580.44 Cr1,662.92 Cr2,007.16 Cr2,154.94 Cr
Total Liabilities --------3,611.74 Cr4,271.46 Cr4,733.05 Cr5,079.83 Cr
Current Liabilities --------2,432.26 Cr3,112.28 Cr3,539.72 Cr3,635.43 Cr
Long Term Debt --------761.42 Cr798.23 Cr645.58 Cr611.34 Cr
Total Debt 888.00 Cr1,094.00 Cr842.00 Cr980.00 Cr1,036.00 Cr1,079.00 Cr1,482.00 Cr-2,015.09 Cr2,577.40 Cr2,763.73 Cr2,518.48 Cr
Total Equity 656.00 Cr790.00 Cr1,331.00 Cr1,483.00 Cr1,558.00 Cr1,770.00 Cr2,597.00 Cr-4,037.53 Cr4,110.95 Cr4,472.56 Cr5,300.06 Cr
Shares Outstanding --------53.87 Cr53.90 Cr53.93 Cr53.99 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -65.00 Cr182.00 Cr332.00 Cr342.00 Cr298.00 Cr347.00 Cr733.00 Cr-993.90 Cr665.69 Cr601.65 Cr1,623.50 Cr
Investing Cash Flow -397.00 Cr-312.00 Cr-289.00 Cr-384.00 Cr-253.00 Cr-221.00 Cr-941.00 Cr--996.06 Cr-822.42 Cr-681.72 Cr-1,088.66 Cr
Financing Cash Flow 486.00 Cr103.00 Cr-54.00 Cr42.00 Cr-45.00 Cr-128.00 Cr255.00 Cr--26.64 Cr249.83 Cr39.28 Cr-524.72 Cr
Capital Expenditure -382.00 Cr-326.00 Cr-277.00 Cr-391.00 Cr-254.00 Cr-222.00 Cr-684.00 Cr--990.16 Cr-678.31 Cr-641.00 Cr-1,069.95 Cr
Free Cash Flow -447.00 Cr-144.00 Cr55.00 Cr-49.00 Cr44.00 Cr125.00 Cr49.00 Cr-3.74 Cr-12.62 Cr-39.35 Cr553.55 Cr
Net Change in Cash 24.00 Cr-27.00 Cr-10.00 Cr1.00 Cr-0-1.00 Cr47.00 Cr--28.80 Cr93.10 Cr-40.79 Cr10.12 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------52.8%50.0%53.9%58.9%
Operating Margin % 10.4%15.5%15.9%14.1%8.4%13.3%28.0%-21.5%7.9%11.4%19.4%
Net Margin % 5.1%7.5%10.0%8.2%4.1%9.0%20.4%-13.1%3.2%6.5%13.2%
ROE % 10.4%17.0%14.3%11.3%6.0%14.4%37.9%-19.6%3.9%8.0%16.8%
ROCE % --------24.8%7.5%10.8%19.0%

Shareholding Pattern

Insiders
32.03%
Institutions
32.59%
Public Float
47.94%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LAURUSLABS

Google News Sat, 15 Aug 2026

Laurus Labs (NSEI:LAURUSLABS) Stock Fair Value Rises After Analysts Lift Growth Expectations - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOZHh2VUpsVWoxVkVyTWQ0S1h4RmRRN0JSclltSGNXRVRSZ25MTEtFbTFEa3E2THF3NHV6MEsteFJJNjVmV0trUU43UGRGem5qLTNmVi1BLTR6MllocFE0NjR0bi1ka0ZVakZkSjN4MDZsdi01NkZtMHk1UFIxbFR2M1huVW9sWm9NbHdkOE…

Google News Fri, 24 Jul 2026

Earnings call transcript: Laurus Labs posts strong Q1 2026 growth, shares rise - Investing.com

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQNlE4cVlUdWk2VHRxekNUZ2lXVVhMOTBUTjlFdHo5bnlCWTNjenRNWlQ1RUZEcEFxRmNEc0JBVHZsTVBnWjZqOVJqLVNEd3hkSk5vb09LUFhkUzA5emNMaE5yNVJEaklVUVYwWXBjaXFVbmQ3TWpPRkRsSnlxbFZJVGJWcnUtaTJYNVM2LW…

Google News Mon, 04 May 2026

Laurus Labs Limited (NSE:LAURUSLABS) Goes Ex-Dividend Soon - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPZ3djWmhMR2c5R3NoZlU0MUdoLXlYU0VmS25CNmpYRXc5SFdtX1p0TEIyajdpVGRyMmxQZWhTWDVNSmc1NHdrckZKemlheW5ZZi16QkZ5SEh3RVlXaTRsMFp0bkp5cko5WFhFam1yUFNPV0g3c0tOTXhaOF92aEVMazBWazROdDM1Q1IzVV…

Google News ue, 28 Jul 2026

10% Returns In Five Days: This Pharma Stock Hits Record High After Q1 Results - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNLWpyQno1QS1GeGhTS04tOVR5cnJhdFc3cUczdmhmNHppSEpIbmVzbzd3cUFzRS1qU3NfUEk4Nkd2Q3JUbVR6QmUxR3NQRlItOWY2QnpnU3IxY25ZZFZiMXNvNkxOTmhpOW11Wk9GNTNPcFhkZjZkOVVZb1RZalQxZGI5REFTR25xeEJOUG…

Google News Mon, 27 Jul 2026

Laurus Labs rallies 4%, up 55% in 5 months; brokerages see more upside - Business Standard

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNaEtGWTZPcDdGU1hTTlh2UjFJSHZfOFVGeUtSczFWSkk0bW9HMVgyZ1N0WHdMcXBBV2JXdzFxeXRsQVJHc2JBQlkwSm1obzdJMWZMU3RSMjB3R2V6dnNucXI4LVlvVlJycTdMblRlbElVbkJHc0RvSXlRLUI3VlhmdUNkSnhNQ2x6S3d6aE…

Google News Fri, 14 Aug 2026

Laurus Labs shares fall 2.03% in Friday's trade - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnp6N3dtMnZ4eF9tUDIzN3ZtV0ZCN2FhenhBelJOZ0FrNFFkWFgzZHI3akREb2J4VUY3eWg3RzVnb2FrUkFyY0JmQW1XRjh3OVlSWDBaZUlBQ3I2djVkNDVRdVZ0cENPcWttYkpmNjhDZ0ZrRjJDRTc3eUlxTDdKOW8tZlFBQVdyT3hQQk…

LAURUSLABS — Frequently Asked Questions

What is the current share price of Laurus Labs Limited (LAURUSLABS)?

As of 2026-09-08 04:53 IST, Laurus Labs Limited (LAURUSLABS) trades at ₹1,840.00 on NSE. Its 52-week range is ₹829.44 to ₹1,938.50.

What is the market capitalisation of LAURUSLABS?

Laurus Labs Limited (LAURUSLABS) has a market capitalisation of ₹99,333.61 Cr on NSE.

What is the P/E ratio of LAURUSLABS?

LAURUSLABS trades at a trailing price-to-earnings (P/E) ratio of 111.85. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 18.79.

Does LAURUSLABS pay a dividend?

Laurus Labs Limited (LAURUSLABS) currently offers a dividend yield of 0.13%.

What is the return on equity (ROE) of LAURUSLABS?

LAURUSLABS has a return on equity (ROE) of 16.77%. Its return on capital employed (ROCE) is 19.53%.

Is LAURUSLABS a good stock to buy?

This page provides a data-driven analysis of Laurus Labs Limited (LAURUSLABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space